Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Clinical Trials

Gedatolisib Therapy Cuts Advanced Breast Cancer Progression by Up to 76% as Shares Soar

An FDA submission is planned for Q4 2025 based on today’s wild-type cohort findings.

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy

FDA Clears MT-125 for First Human Trials in Treatment-Resistant Glioblastoma

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

Eli Lilly to Acquire Verve Therapeutics as Gene-Editing Trial Begins

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy

Paytm Rallies to ₹950 as Defence, Railway and Infrastructure Stocks Climb

GPT-4 Identifies Existing Drug Combinations That Kill Breast Cancer Cells

Alzheimer’s Drug Trials Surge 11% in 2025 as NICE Reviews Lecanemab and Donanemab

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex

Trump Orders U.S. Drug Prices Tied to Lowest OECD Rates, Sparking Concerns Over Global Impact

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

Pfizer Halts Development of Oral Weight-Loss Pill After Liver Injury

FDA Rejects Aldeyra's Reproxalap NDA for Dry Eye Disease Over Efficacy Issues

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials

Google DeepMind Spinoff Plans AI-Designed Drug Trials by Year-End